235 related articles for article (PubMed ID: 32440811)
61. C-MET inhibitors for advanced non-small cell lung cancer.
Pasquini G; Giaccone G
Expert Opin Investig Drugs; 2018 Apr; 27(4):363-375. PubMed ID: 29621416
[TBL] [Abstract][Full Text] [Related]
62. EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment.
Brugger W; Thomas M
Lung Cancer; 2012 Jul; 77(1):2-8. PubMed ID: 22281074
[TBL] [Abstract][Full Text] [Related]
63. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
Ludovini V; Bianconi F; Pistola L; Pistola V; Chiari R; Colella R; Bellezza G; Tofanetti FR; Siggillino A; Baldelli E; Flacco A; Giuffrida D; Sidoni A; Crinò L
Cancer Chemother Pharmacol; 2012 May; 69(5):1289-99. PubMed ID: 22302407
[TBL] [Abstract][Full Text] [Related]
64. Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Botting GM; Rastogi I; Chhabra G; Nlend M; Puri N
PLoS One; 2015; 10(8):e0136155. PubMed ID: 26301867
[TBL] [Abstract][Full Text] [Related]
65. MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
Sakai A; Kasahara K; Ohmori T; Kimura H; Sone T; Fujimura M; Nakao S
J Thorac Oncol; 2012 Sep; 7(9):1337-44. PubMed ID: 22722827
[TBL] [Abstract][Full Text] [Related]
66. Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.
Kim S; Kim TM; Kim DW; Kim S; Kim M; Ahn YO; Keam B; Heo DS
Cancer Res Treat; 2019 Jul; 51(3):951-962. PubMed ID: 30309221
[TBL] [Abstract][Full Text] [Related]
67. Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?
Wu YL; Soo RA; Locatelli G; Stammberger U; Scagliotti G; Park K
Cancer Treat Rev; 2017 Dec; 61():70-81. PubMed ID: 29121501
[TBL] [Abstract][Full Text] [Related]
68. [Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC].
Brosseau S; Oulkhouir Y; Naltet C; Zalcman G
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S27-33. PubMed ID: 26118873
[TBL] [Abstract][Full Text] [Related]
69. Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.
Facchinetti F; Proto C; Minari R; Garassino M; Tiseo M
Handb Exp Pharmacol; 2018; 249():63-89. PubMed ID: 28332047
[TBL] [Abstract][Full Text] [Related]
70. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
71. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
72. Targeting MET: Discovery of Small Molecule Inhibitors as Non-Small Cell Lung Cancer Therapy.
Wang C; Lu X
J Med Chem; 2023 Jun; 66(12):7670-7697. PubMed ID: 37262349
[TBL] [Abstract][Full Text] [Related]
73. De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors.
Li JW; Cao SH; Xu JL; Zhong H
Cancer Biol Ther; 2019; 20(9):1183-1186. PubMed ID: 31131689
[TBL] [Abstract][Full Text] [Related]
74. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
[TBL] [Abstract][Full Text] [Related]
75. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
[TBL] [Abstract][Full Text] [Related]
76. Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment.
Choi DY; You S; Jung JH; Lee JC; Rho JK; Lee KY; Freeman MR; Kim KP; Kim J
Proteomics; 2014 Aug; 14(16):1845-56. PubMed ID: 24946052
[TBL] [Abstract][Full Text] [Related]
77. Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?
Watermann I; Schmitt B; Stellmacher F; Müller J; Gaber R; Kugler Ch; Reinmuth N; Huber RM; Thomas M; Zabel P; Rabe KF; Jonigk D; Warth A; Vollmer E; Reck M; Goldmann T
Diagn Pathol; 2015 Jul; 10():130. PubMed ID: 26215852
[TBL] [Abstract][Full Text] [Related]
78. [Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer].
Jiang T; Zhou C
Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):240-4. PubMed ID: 25936889
[TBL] [Abstract][Full Text] [Related]
79. [Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing].
Liang H; Wang M
Zhongguo Fei Ai Za Zhi; 2015 Dec; 18(12):745-51. PubMed ID: 26706951
[TBL] [Abstract][Full Text] [Related]
80. Met inhibitors in the treatment of lung cancer: the evidence to date.
Hamilton G; Rath B
Expert Opin Pharmacother; 2022 May; 23(7):815-825. PubMed ID: 35377279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]